

China's COVID vaccines have been crucial " now im

Nature

598, 398-399

DOI: [10.1038/d41586-021-02796-w](https://doi.org/10.1038/d41586-021-02796-w)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Sinopharm's BBIBP-CorV Vaccine Effectiveness on Preventing Hospital Admission and Deaths: Results From a Retrospective Study in the Emirate of Abu Dhabi, United Arab Emirates (UAE). SSRN Electronic Journal, 0, , .	0.4	5
2	Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine. Vaccines, 2022, 10, 86.	2.1	62
4	Acceptance of a Third Dose of COVID-19 Vaccine and Associated Factors in China Based on Health Belief Model: A National Cross-Sectional Study. Vaccines, 2022, 10, 89.	2.1	43
6	Waning antibody levels after COVID-19 vaccination with mRNA Comirnaty and inactivated CoronaVac vaccines in blood donors, Hong Kong, April 2020 to October 2021. Eurosurveillance, 2022, 27, .	3.9	30
7	Managing waning vaccine protection against SARS-CoV-2 variants. Lancet, The, 2022, 399, 2-3.	6.3	18
8	Prospective Evaluation of Side-Effects Following the First Dose of Oxford/AstraZeneca COVID-19 Vaccine among Healthcare Workers in Saudi Arabia. Vaccines, 2022, 10, 223.	2.1	17
10	Neutralizing antibody titers elicited by CoronaVac and BNT162b2 vaccines in health care workers with and without prior SARS-CoV-2 infection. Journal of Travel Medicine, 2022, 29, .	1.4	3
11	Effectiveness of Inactivated COVID-19 Vaccines Against Illness Caused by the B.1.617.2 (Delta) Variant During an Outbreak in Guangdong, China. Annals of Internal Medicine, 2022, 175, 533-540.	2.0	52
12	The allocation of COVID-19 vaccines and antivirals against emerging SARS-CoV-2 variants of concern in East Asia and Pacific region: A modelling study. The Lancet Regional Health - Western Pacific, 2022, 21, 100389.	1.3	16
13	Children and adolescents in African countries should also be vaccinated for COVID-19. BMJ Global Health, 2022, 7, e008315.	2.0	14
14	Effectiveness of inactivated SARS-CoV-2 vaccine (CoronaVac) on intensive care unit survival. Epidemiology and Infection, 2022, 150, 1-18.	1.0	5
15	Booster doses for inactivated COVID-19 vaccines: if, when, and for whom. Lancet Infectious Diseases, The, 2022, 22, 430-432.	4.6	15
16	Can a combination of vaccination and face mask wearing contain the COVID-19 pandemic?. Microbial Biotechnology, 2022, 15, 721-737.	2.0	41
17	Kinetics and Factors Associated With 12-Month Persistence of Neutralizing Antibody Induced by Two Inactivated COVID-19 Vaccines. SSRN Electronic Journal, 0, , .	0.4	0
18	COVID-19 Vaccine: Between Myth and Truth. Vaccines, 2022, 10, 349.	2.1	12
19	Humoral and cellular responses to vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose with BNT162b2. Journal of Infection, 2022, 84, 834-872.	1.7	9
21	Antibody and T Cell Responses against SARS-CoV-2 Elicited by the Third Dose of BBIBP-CorV (Sinopharm) and BNT162b2 (Pfizer-BioNTech) Vaccines Using a Homologous or Heterologous Booster Vaccination Strategy. Vaccines, 2022, 10, 539.	2.1	24
22	Ocular Adverse Events after Inactivated COVID-19 Vaccination in Xiamen. Vaccines, 2022, 10, 482.	2.1	26

#	ARTICLE	IF	CITATIONS
23	Impact of the Sinopharm's BBIBP-CorV vaccine in preventing hospital admissions and death in infected vaccinees: Results from a retrospective study in the emirate of Abu Dhabi, United Arab Emirates (UAE). <i>Vaccine</i> , 2022, 40, 2003-2010.	1.7	39
24	The COVID-19 Health Crisis and Its Impact on China's International Relations. <i>Journal of Risk and Financial Management</i> , 2022, 15, 123.	1.1	9
25	Neutralizing Activities Against the Omicron Variant After a Heterologous Booster in Healthy Adults Receiving Two Doses of CoronaVac Vaccination. <i>Journal of Infectious Diseases</i> , 2022, 226, 1372-1381.	1.9	41
26	COVID-19 vaccination: The road ahead. <i>Science</i> , 2022, 375, 1127-1132.	6.0	134
27	Using a systems therapeutic for physiological renormalization approach to vaccine development. Covid-19 as an example. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-2.	1.4	1
28	Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study. <i>Lancet Infectious Diseases</i> , 2022, 22, 791-801.	4.6	84
29	Differential neutralizing antibody responses elicited by CoronaVac and BNT162b2 against SARS-CoV-2 Lambda in Chile. <i>Nature Microbiology</i> , 2022, 7, 524-529.	5.9	22
30	Strategies and safety considerations of booster vaccination in COVID-19. <i>Bosnian Journal of Basic Medical Sciences</i> , 2022, , .	0.6	5
31	Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines. <i>EBioMedicine</i> , 2022, 79, 103986.	2.7	23
35	Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1338-1340.	0.5	1
38	Effectiveness of Sputnik V, Qazvac, Hayat-Vax, and Coronavac Vaccines in Preventing COVID-19 in Kazakhstan, February-September 2021. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
39	Dealing with a mucosal viral pandemic: lessons from COVID-19 vaccines. <i>Mucosal Immunology</i> , 2022, 15, 584-594.	2.7	41
40	Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale prospective cohort study. <i>The Lancet Global Health</i> , 2022, 10, e798-e806.	2.9	141
41	Heterologous immunization with inactivated vaccine followed by mRNA-booster elicits strong immunity against SARS-CoV-2 Omicron variant. <i>Nature Communications</i> , 2022, 13, 2670.	5.8	108
42	SARS-CoV-2 accessory proteins reveal distinct serological signatures in children. <i>Nature Communications</i> , 2022, 13, .	5.8	22
44	Risk of serious adverse events after the BNT162b2, CoronaVac, and ChAdOx1 vaccines in Malaysia: A self-controlled case series study. <i>Vaccine</i> , 2022, 40, 4394-4402.	1.7	22
45	Covid-19, an unfinished story. <i>Presse Medicale</i> , 2022, 51, 104131.	0.8	8
46	Omicron Reactive Multi Protein Specific CD4 T Cells Defines Cellular Immune Response Induced by Inactivated Virus Vaccines. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2

#	ARTICLE	IF	CITATIONS
47	Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. <i>Clinical and Experimental Vaccine Research</i> , 2022, 11, 209.	1.1	4
48	Imaging Severity COVID-19 Assessment in Vaccinated and Unvaccinated Patients: Comparison of the Different Variants in a High Volume Italian Reference Center. <i>Journal of Personalized Medicine</i> , 2022, 12, 955.	1.1	9
50	Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study. <i>BMJ</i> , The, 0, , e070102.	3.0	10
51	Knowledge, Attitudes, and Practices of Adult Iraqi Population Towards COVID-19 Booster Dose: A Cross-Sectional Study. <i>Patient Preference and Adherence</i> , 0, Volume 16, 1525-1537.	0.8	4
52	Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies. <i>BMC Medicine</i> , 2022, 20, .	2.3	13
53	A Testing and Quarantine Algorithm for Individual International Travelers Using Published Data on WHO-Approved Vaccines and Bayesâ€™ Theorem. <i>Vaccines</i> , 2022, 10, 902.	2.1	3
54	Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. <i>Nature Communications</i> , 2022, 13, .	5.8	42
55	Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans. <i>Scientific Reports</i> , 2022, 12, .	1.6	7
56	Advances in COVID-19 Vaccines and New Coronavirus Variants. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	4
57	Safety of an inactivated, whole-virion COVID-19 vaccine (CoronaVac) in people aged 60 years or older in Hong Kong: a modified self-controlled case series. <i>The Lancet Healthy Longevity</i> , 2022, 3, e491-e500.	2.0	24
58	Immunogenicity Following Two Doses of the BBIBP-CorV Vaccine and a Third Booster Dose with a Viral Vector and mRNA COVID-19 Vaccines against Delta and Omicron Variants in Prime Immunized Adults with Two Doses of the BBIBP-CorV Vaccine. <i>Vaccines</i> , 2022, 10, 1071.	2.1	14
59	Vacunas contra la COVID-19. <i>Ambiociencias</i> , 0, , 75-108.	0.0	1
60	Humoral immune response characterization of heterologous prime-boost vaccination with CoronaVac and BNT162b2. <i>Vaccine</i> , 2022, 40, 5189-5196.	1.7	9
61	CoronaVac: A review of efficacy, safety, and immunogenicity of the inactivated vaccine against SARS-CoV-2. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	25
62	Effectiveness of BNT162b2 and CoronaVac vaccinations against mortality and severe complications after SARS-CoV-2 Omicron BA.2 infection: a caseâ€™control study. <i>Emerging Microbes and Infections</i> , 2022, 11, 2304-2314.	3.0	36
63	Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	2
64	Three-Dose Primary Series of Inactivated COVID-19 Vaccine for Persons Living with HIV, Hong Kong. <i>Emerging Infectious Diseases</i> , 2022, 28, 2130-2132.	2.0	5
65	Profile of Brazilian inpatients with COVID-19 vaccine breakthrough infection and risk factors for unfavorable outcome. <i>Revista Panamericana De Salud Publica/Pan American Journal of Public Health</i> , 0, , 1-10.	0.6	3

#	ARTICLE	IF	CITATIONS
66	Factors associated with neutralizing antibody levels induced by two inactivated COVID-19 vaccines for 12 months after primary series vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
67	A global epidemiological analysis of COVID-19 vaccine types and clinical outcomes. <i>International Journal of Infectious Diseases</i> , 2022, 124, 206-211.	1.5	4
68	Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, .	1.4	5
69	Current clinical status of new COVID-19 vaccines and immunotherapy. <i>Environmental Science and Pollution Research</i> , 0, , .	2.7	5
70	Humoral Immune Response of BNT162b2 and CoronaVac Vaccinations in Hemodialysis Patients: A Multicenter Prospective Cohort. <i>Vaccines</i> , 2022, 10, 1542.	2.1	9
71	A comparative characterization of SARS-CoV-2-specific T _H 1 cells induced by mRNA or inactivated virus COVID-19 vaccines. <i>Cell Reports Medicine</i> , 2022, 3, 100793.	3.3	26
73	Inactivated Covid-19 vaccine did not undermine live birth and neonatal outcomes of women with frozen-thawed embryo transfer. <i>Human Reproduction</i> , 2022, 37, 2942-2951.	0.4	16
74	Comparison of the Safety and Immunogenicity of FAKHRAVAC and BBIBP-CorV Vaccines when Administrated as Booster Dose: A Parallel Two Arms, Randomized, Double Blind Clinical Trial. <i>Vaccines</i> , 2022, 10, 1800.	2.1	5
75	Priming conditions shape breadth of neutralizing antibody responses to sarbecoviruses. <i>Nature Communications</i> , 2022, 13, .	5.8	7
76	Integrated Multi-Omic Characterization of the Detachment Process of Adherent Vero Cells with Animal-Based and Animal-Origin-Free Enzymes. <i>Cells</i> , 2022, 11, 3396.	1.8	0
77	Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis. <i>International Journal of Infectious Diseases</i> , 2022, 124, 212-223.	1.5	21
78	Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial. <i>Vaccines</i> , 2022, 10, 1865.	2.1	8
79	Protection from infection or disease? Re-evaluating the broad immunogenicity of inactivated SARS-CoV-2 vaccines. <i>Virologica Sinica</i> , 2022, 37, 783-785.	1.2	2
80	The evolution of the global COVID-19 epidemic in Morocco and understanding the different therapeutic approaches of chitosan in the control of the pandemic. <i>Polymer Bulletin</i> , 0, , .	1.7	4
81	Anti-SARS-CoV-2 IgG Antibodies Post-COVID-19 or Post-Vaccination in Libyan Population: Comparison of Four Vaccines. <i>Vaccines</i> , 2022, 10, 2002.	2.1	7
82	Neutralizing antibodies induced by homologous and heterologous boosters in CoronaVac vaccines in Chile. <i>Clinical Microbiology and Infection</i> , 2023, 29, 541.e1-541.e7.	2.8	2
83	SARS-CoV-2 vaccination-infection pattern imprints and diversifies T cell differentiation and neutralizing response against Omicron subvariants. <i>Cell Discovery</i> , 2022, 8, .	3.1	3
84	COVID-19 Vaccines, Effectiveness, and Immune Responses. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15415.	1.8	9

#	ARTICLE	IF	CITATIONS
85	Humoral and cellular immunity of two-dose inactivated COVID-19 vaccination in Chinese children: A prospective cohort study. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	2
86	Effectiveness of BNT162b2 and CoronaVac in children and adolescents against SARS-CoV-2 infection during Omicron BA.2 wave in Hong Kong. <i>Communications Medicine</i> , 2023, 3, .	1.9	14
87	An inactivated SARS-CoV-2 vaccine induced cross-neutralizing persisting antibodies and protected against challenge in small animals. <i>IScience</i> , 2023, 26, 105949.	1.9	1
89	Immunogenicity and reactogenicity of heterologous immunization schedules with COVID-19 vaccines: a systematic review and network meta-analysis. <i>Chinese Medical Journal</i> , 2023, 136, 24-33.	0.9	2
90	Structural and Immunoreactivity Properties of the SARS-CoV-2 Spike Protein upon the Development of an Inactivated Vaccine. <i>Viruses</i> , 2023, 15, 480.	1.5	4
91	Is a new COVID-19 wave coming from China due to an unknown variant of concern? Keep calm and look at the data. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	4
92	COVID-19 Therapeutics: Use, Mechanism of Action, and Toxicity (Vaccines, Monoclonal Antibodies, and) Tj ETQq0 0,0 rgBT /Overlock 100,8	0.8	8
94	Combating COVID-19 Vaccine Inequity During the Early Stages of the COVID-19 Pandemic. <i>Journal of Racial and Ethnic Health Disparities</i> , 2024, 11, 621-630.	1.8	1
95	COVID-19 Vaccination Coverage among 42,565 Adults Amid the Spread of Omicron Variant in Beijing, China. <i>Vaccines</i> , 2023, 11, 739.	2.1	2
96	Chinese Anti-Westernism on social media. <i>Annual Review of Social Partnerships</i> , 2023, 8, 119-137.	1.2	1
97	Redistribution and Activation of CD16brightCD56dim NK Cell Subset to Fight against Omicron Subvariant BA.2 after COVID-19 Vaccination. <i>Microorganisms</i> , 2023, 11, 940.	1.6	1
98	Non-spike and spike-specific memory T cell responses after the third dose of inactivated COVID-19 vaccine. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	4
99	Boosting in the age of Omicron. <i>ELife</i> , 0, 12, .	2.8	0
100	Effectiveness of an inactivated SARS-CoV-2 vaccine in children and adolescents: a large-scale observational study. <i>The Lancet Regional Health Americas</i> , 2023, 21, 100487.	1.5	2
112	Effectiveness of inactivated COVID-19 vaccine against the severity of Omicron variant. <i>Frontiers of Medicine</i> , 0, , .	1.5	0
116	Antibody titers of individuals vaccinated for COVID-19: A systematic review. <i>Journal of Biosciences</i> , 2023, 48, .	0.5	0